Pharmaniaga Group assured that the Sinovac’s vaccine against Covid-19 will prevent severe manifestations of the disease after various research groups reported seemingly conflicting figures for the vaccine’s efficacy rate.

The company's head of research and development, Badarulhisam Abdul Rahman, highlighted that in the Brazil trial, which had reported an overall efficacy of 50.38 percent, none of the vaccine recipients required hospitalisation...